Enliven Therapeutics (ELVN) Net Equity Issued and Repurchased (2019 - 2023)

Enliven Therapeutics (ELVN) has 3 years of Net Equity Issued and Repurchased data on file, last reported at -$1.5 million in Q2 2023.

• For the quarter ending Q2 2023, Net Equity Issued and Repurchased changed N/A year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2024 stood at -$1.5 million (down 100.94% YoY), and the FY2023 full-year result was $161.4 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased slipped to -$1.5 million in Q2 2023, from $162.9 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $162.9 million in Q1 2023 to a low of -$1.5 million in Q2 2023.
• A 3-year average of $44.8 million and a median of $17.2 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 60.96% in 2020, while the deepest fall reached 60.96% in 2020.
• Tracing ELVN's Net Equity Issued and Repurchased over 3 years: stood at $1.6 million in 2019, then jumped by 940.66% to $17.2 million in 2020, then plunged by 108.95% to -$1.5 million in 2023.
• Business Quant data shows ELVN's Net Equity Issued and Repurchased at -$1.5 million in Q2 2023, $162.9 million in Q1 2023, and $17.2 million in Q1 2020.